Repligen Corporation Profile Avatar - Palmy Investing

Repligen Corporation

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding com…

Medical - Instruments & Supplies
US, Waltham [HQ]

Cash Flow Statements

14 Records · Starting from 2010
In Million USD. Margins, Growth Rates In %
Metric 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-2.00 3.00 13.00 25.00 18.00 15.00 7.00 17.00 32.00 67.00 62.00 119.00 172.00 113.00
Operating Cash (Net)
-2.00 3.00 13.00 25.00 18.00 15.00 7.00 17.00 32.00 67.00 62.00 119.00 172.00 113.00
Accounts Receivable
- - - - -1.00 - - -1.00 -3.00 -3.00 -6.00 -6.00 -7.00 -21.00 -46.00 -3.00 -3.00
Accounts Payable
- - - - 1.00 - - 2.00 3.00 -1.00 - - 2.00 - - 2.00 19.00 -8.00 -9.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
9.00 -1.00 2.00 -17.00 -19.00 4.00 -49.00 -98.00 -14.00 -205.00 -201.00 -221.00 -233.00 -123.00
Capital Expenditure
- - - - -1.00 -4.00 -5.00 -2.00 -4.00 -5.00 -14.00 -23.00 -26.00 -71.00 -133.00 -38.00
Purchases of Investments
-47.00 -84.00 -39.00 -42.00 -27.00 -20.00 -23.00 - - - - - - - - - - -100.00 - -
Sale/Maturity of Investment
59.00 83.00 43.00 29.00 34.00 27.00 23.00 19.00 - - - - - - - - - - 102.00
Property, Plant, Equipment (P&PE)
- - - - -1.00 -4.00 -5.00 -2.00 -4.00 -5.00 -14.00 -23.00 -26.00 -71.00 -133.00 -38.00
Acquisitions (Net)
-1.00 - - -43,214.00 -29,208.00 -21.00 -27.00 -44.00 -112.00 - - -182.00 -175.00 -149.00 - - -186.00
Other Investing Activities
- - - - 43,214.00 29,208.00 - - 27.00 - - - - - - -4.00 -3.00 -4.00 - - - -
Financing Activities
Used Cash (Net)
- - - - -1.00 -2.00 -1.00 - - -112.00 -129.00 -3.00 -484.00 -305.00 - - -13.00 -248.00
Debt Repayment
- - - - - - - - - - - - - - - - - - -114.00 - - - - - - -282.00
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - - - - - - - - - - - - - - - 321 297 85 20 15
Other Financing Activities
- - - - 1.00 2.00 1.00 - - 112.00 - - 3.00 280.00 8.00 -76.00 17.00 -20.00
Cash Balances
Begin of Period
5.00 12.00 11.00 29.00 39.00 35.00 54.00 122.00 173.00 193.00 537.00 717.00 603.00 523.00
End of Period
12.00 14.00 29.00 39.00 35.00 54.00 122.00 173.00 193.00 537.00 717.00 603.00 523.00 751.00
Change
7.00 1.00 18.00 10.00 -4.00 18.00 68.00 51.00 20.00 343.00 179.00 -113.00 -80.00 227.00
Non-Cash Balances
Depreciation and Amortization
1.00 1.00 3.00 3.00 4.00 4.00 5.00 10.00 15.00 20.00 27.00 38.00 50.00 68.00
Stock Based Compensation
1.00 1.00 1.00 1.00 1.00 3.00 4.00 6.00 - - 12.00 17.00 27.00 27.00 25.00
Other
- - - - - - - - 2.00 4.00 5.00 4.00 4.00 13.00 11.00 20.00 -27.00 -14.00
Highlighted metrics
Free Cash Flow (FCF)
-3.00 2.00 12.00 21.00 12.00 12.00 3.00 11.00 18.00 44.00 36.00 47.00 38.00 74.00
Cash Conversion Cycle (CCC)
130.00 102.00 195.00 210.00 157.00 166.00 208.00 244.00 202.00 192.00 253.00 257.00 275.00 259.00
Invested Capital
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of RGEN's Analysis
CIK: 730272 CUSIP: 759916109 ISIN: US7599161095 LEI: - UEI: -
Secondary Listings
RGEN has no secondary listings inside our databases.